A bioinformatics-guided platform selects and standardizes mushroom-derived polysaccharides and fungal fibers that can be used at small doses in processed foods.
Solution Effectiveness
The company reported that an early fungal prebiotic increased microbiota function by up to 500% with 100% efficacy in its in-vitro comparison. A human study has been registered to compare fungal and plant fibers for gut-related outcomes.
Investment Funding
Last Funding Stage
Non-equity Assistance
Total Funding Amount
200.K
Last Funding Date
15-04-2025
Startup Stage
Seed
Lead Investors
Big Idea Ventures, LvlUp Ventures, GRID EXPONENTIAL
People
Founders
Martin Larre
About
We are a biotech company Transforming Health through the Microbiome. Future Biome develops next generation prebiotics: Precision fungi-based prebiotics to combat this inflammation with predictable efficacy. The Technology we are developing for this consists of a predictive bioinformatic platform. Our Platform customizes the best fungal prebiotic for each microbiota or market segment, to increase efficacy an effects. We can developed personalized and semi personalized fungal prebiotics. 
 Our First Fungal Prebiotic increased microbiota function up to 500% with 100% efficacy in our in vitro studies against market reference.We are starting clinical trials with these first fungal prebiotic in April 2024
Products
Product
BiotaBliss branded microbiome ingredient platform for immunity, energy, mood and gut comfort applications in food products.
Star Product
BiotaBliss, because it is the named commercial ingredient platform presented on the company website.
Demo Product or Complete Product?
Ingredient-development and clinical-validation stage.
Awards and Recognitions
Participations
Participated in programs and ecosystems including Big Idea Ventures, Microsoft for Startups, GridX, Forward Fooding and Hello Tomorrow Deep Tech Pioneers.
Something missing or incorrect on this page? Help us enrich this information
